Acura


Company Update (NASDAQ:ACUR): Acura Pharmaceuticals, Inc. to Raise Approximately $7.6 Million From Institutional Healthcare Investors

Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) announced it has entered into a Securities Purchase Agreement with certain institutional investors to sell 9,790,000 shares of common stock …

Company Update (NASDAQ:ACUR): Acura Pharmaceuticals, Inc. USPTO Issues Notice of Allowance for Novel Limitx(TM) Abuse Deterrent Technology

Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company innovating abuse deterrent drugs, announced receipt from the United States Patent and Trademark Office (“USPTO”) …

Company Update (NASDAQ:ACUR): Acura Pharmaceuticals, Inc. Partners Its Methamphetamine Resistant Impede(R) Technology

Acura Pharmaceuticals, Inc. (NASDAQ:ACUR) announced that Acura has entered into a License and Development Agreement with Bayer Healthcare LLC to provide an exclusive worldwide …

Stock Update (NASDAQ:ACUR): Acura Pharmaceuticals, Inc. Announces First Quarter 2015 Financial Results

Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), a specialty pharmaceutical company developing products intended to address medication abuse and misuse, announced today financial results for the first …

Stock Update (NASDAQ:ACUR): Acura Pharmaceuticals, Inc. to Develop Abuse Deterrent Hydrocodone With Acetaminophen Tablets, Limitx Technology

Acura Pharmaceuticals, Inc. (NASDAQ:ACUR), announced that it is initiating development of an immediate-release hydrocodone bitartrate with acetaminophen tablet (“hydrocodone/APAP”) incorporating Acura’s novel LIMITX™ …

Acura Quarterly Update; Roth Capital Reiterates Buy

Roth Capital analyst Ed Arce reiterated a Buy rating on Acura (NASDAQ:ACUR) with a price target of $1.50, which represents a potential upside …

Roth Capital Reiterates Buy On Acura Following Positive PK Results

In a research report issued today, Roth Capital analyst Ed Arce reiterated a Buy rating on Acura (NASDAQ:ACUR) with a $1.50 price target, …

Roth Capital Remains Bullish On Acura Following Submission Of Dispute Resolution Request To FDA

In a research report issued today, Roth Capital analyst Ed Arce maintained a Buy rating on Acura (NASDAQ:ACUR) with a $1.50 price target, following …

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts